Literature DB >> 22069219

Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms.

Hua Zhang1, Jeffrey L Bennett, A S Verkman.   

Abstract

OBJECTIVE: Neuromyelitis optica (NMO) is a neuroinflammatory disease of spinal cord and optic nerve associated with serum autoantibodies (NMO-immunoglobulin G [IgG]) against astrocyte water channel aquaporin-4 (AQP4). Recent studies suggest that AQP4 autoantibodies are pathogenic. The objectives of this study were to establish an ex vivo spinal cord slice model in which NMO-IgG exposure produces lesions with characteristic NMO pathology, and to test the involvement of specific inflammatory cell types and soluble factors.
METHODS: Vibratome-cut transverse spinal cord slices were cultured on transwell porous supports. After 7 days in culture, spinal cord slices were exposed to NMO-IgG and complement for 1 to 3 days. In some studies inflammatory cells or factors were added. Slices were examined for glial fibrillary acidic protein (GFAP), AQP4, and myelin immunoreactivity.
RESULTS: Spinal cord cellular structure, including astrocytes, microglia, neurons, and myelin, was preserved in culture. NMO-IgG bound strongly to astrocytes in the spinal cord slices. Slices exposed to NMO-IgG and complement showed marked loss of GFAP, AQP4, and myelin. Lesions were not seen in the absence of complement or in spinal cord slices from AQP4 null mice. In cultures treated with submaximal NMO-IgG, the severity of NMO lesions was increased with inclusion of neutrophils, natural killer cells, or macrophages, or the soluble factors tumor necrosis factor α (TNFα), interleukin-6 (IL-6), IL-1β, or interferon-γ. Lesions were also produced in ex vivo optic nerve and hippocampal slice cultures.
INTERPRETATION: These results provide evidence for AQP4, complement- and NMO-IgG-dependent NMO pathogenesis in spinal cord, and implicate the involvement of specific immune cells and cytokines. Our ex vivo model allows for direct manipulation of putative effectors of NMO disease pathogenesis in a disease-relevant tissue.
Copyright © 2011 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22069219      PMCID: PMC3319401          DOI: 10.1002/ana.22551

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  33 in total

1.  Generation and phenotype of a transgenic knockout mouse lacking the mercurial-insensitive water channel aquaporin-4.

Authors:  T Ma; B Yang; A Gillespie; E J Carlson; C J Epstein; A S Verkman
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  A simple method for organotypic cultures of nervous tissue.

Authors:  L Stoppini; P A Buchs; D Muller
Journal:  J Neurosci Methods       Date:  1991-04       Impact factor: 2.390

3.  Optical measurement of swelling and water transport in spinal cord slices from aquaporin null mice.

Authors:  E I Solenov; L Vetrivel; Kotaro Oshio; Geoffrey T Manley; A S Verkman
Journal:  J Neurosci Methods       Date:  2002-01-15       Impact factor: 2.390

4.  Phagocytosis of Mycobacterium leprae by human monocyte-derived macrophages is mediated by complement receptors CR1 (CD35), CR3 (CD11b/CD18), and CR4 (CD11c/CD18) and IFN-gamma activation inhibits complement receptor function and phagocytosis of this bacterium.

Authors:  L S Schlesinger; M A Horwitz
Journal:  J Immunol       Date:  1991-09-15       Impact factor: 5.422

5.  The mercurial insensitive water channel (AQP-4) forms orthogonal arrays in stably transfected Chinese hamster ovary cells.

Authors:  B Yang; D Brown; A S Verkman
Journal:  J Biol Chem       Date:  1996-03-01       Impact factor: 5.157

6.  Proinflammatory role of aquaporin-4 in autoimmune neuroinflammation.

Authors:  Lihua Li; Hua Zhang; Michel Varrin-Doyer; Scott S Zamvil; A S Verkman
Journal:  FASEB J       Date:  2011-01-21       Impact factor: 5.191

7.  An open label study of the effects of rituximab in neuromyelitis optica.

Authors:  B A C Cree; S Lamb; K Morgan; A Chen; E Waubant; C Genain
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

8.  Expression and function of membrane regulators of complement on rat astrocytes in culture.

Authors:  C A Rogers; P Gasque; S J Piddlesden; N Okada; V M Holers; B P Morgan
Journal:  Immunology       Date:  1996-05       Impact factor: 7.397

9.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.

Authors:  Vanda A Lennon; Dean M Wingerchuk; Thomas J Kryzer; Sean J Pittock; Claudia F Lucchinetti; Kazuo Fujihara; Ichiro Nakashima; Brian G Weinshenker
Journal:  Lancet       Date:  2004 Dec 11-17       Impact factor: 79.321

Review 10.  Microglia and macrophage activation and the regulation of complement-receptor-3 (CR3/MAC-1)-mediated myelin phagocytosis in injury and disease.

Authors:  Shlomo Rotshenker
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

View more
  75 in total

1.  White matter disease: A novel approach to treatment of neuromyelitis optica.

Authors:  Heather Wood
Journal:  Nat Rev Neurol       Date:  2011-11-22       Impact factor: 42.937

Review 2.  Aquaporin 4 and neuromyelitis optica.

Authors:  Marios C Papadopoulos; A S Verkman
Journal:  Lancet Neurol       Date:  2012-05-16       Impact factor: 44.182

Review 3.  The innate immune system in demyelinating disease.

Authors:  Lior Mayo; Francisco J Quintana; Howard L Weiner
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

4.  Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica.

Authors:  Julien Ratelade; Nithi Asavapanumas; Alanna M Ritchie; Scott Wemlinger; Jeffrey L Bennett; A S Verkman
Journal:  Acta Neuropathol       Date:  2013-08-31       Impact factor: 17.088

5.  Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica.

Authors:  Lukmanee Tradtrantip; Hua Zhang; Marc O Anderson; Samira Saadoun; Puay-Wah Phuan; Marios C Papadopoulos; Jeffrey L Bennett; A S Verkman
Journal:  FASEB J       Date:  2012-02-08       Impact factor: 5.191

6.  Optic neuritis in neuromyelitis optica.

Authors:  Marc H Levin; Jeffrey L Bennett; A S Verkman
Journal:  Prog Retin Eye Res       Date:  2013-03-30       Impact factor: 21.198

7.  Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid cause demyelination of spinal cord explants.

Authors:  Kevin Blauth; John Soltys; Adeline Matschulat; Cory R Reiter; Alanna Ritchie; Nicholas L Baird; Jeffrey L Bennett; Gregory P Owens
Journal:  Acta Neuropathol       Date:  2015-10-28       Impact factor: 17.088

Review 8.  Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO.

Authors:  A S Verkman; Puay-Wah Phuan; Nithi Asavapanumas; Lukmanee Tradtrantip
Journal:  Brain Pathol       Date:  2013-11       Impact factor: 6.508

Review 9.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

10.  Visualization of inflammation and demyelination in 2D2 transgenic mice with rodent MRI.

Authors:  Jordan C Bell; Qingwei Liu; Yan Gan; Qiang Liu; Yaou Liu; Fu-Dong Shi; Gregory H Turner
Journal:  J Neuroimmunol       Date:  2013-09-18       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.